Clinical Trial Update: Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating clinical outcomes and biomarkers predicting immune response to imiquimod in cervical intraepithelial neoplasia grade 2/3 (HSIL); recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia

Drugs mentioned

• Imiquimod (imiquimod)

Snippet

Sponsor: Barretos Cancer Hospital | Conditions: HSIL, High-Grade Squamous Intraepithelial Lesions, Vaginal Microbiome | Phase 4 | Status: RECRUITING